Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety and Effectiveness of IPN10200 and Botulinum Toxin Type A for Adults with Moderate to Severe Upper Facial Lines

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of moderate to severe upper facial lines, which are common concerns for many adults. The study will evaluate a new treatment called IPN10200, which is a type of botulinum toxin used to improve the appearance of these facial lines. Participants in the study will receive either the IPN10200 treatment or a placebo, which is a substance with no active medication, to compare the effects.

The purpose of the study is to assess the safety and effectiveness of IPN10200 in reducing the appearance of facial lines. The study will involve a series of visits where participants will receive injections and have their facial lines assessed by both doctors and themselves. The study will last for several weeks, with the main assessment taking place on Day 29 after the treatment. Participants will be monitored for any side effects and changes in their facial lines throughout the study.

During the study, participants will be asked to attend regular check-ups to monitor their health and the effects of the treatment. These check-ups will include physical examinations and assessments of facial lines. The study aims to find the best dose of IPN10200 that is both safe and effective in improving the appearance of facial lines. The results will help determine if IPN10200 can be a useful treatment option for people with moderate to severe upper facial lines.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants are required to provide informed consent, confirming their understanding and agreement to comply with the study requirements.

    Participants must be between 18 and 65 years old and have moderate to severe upper facial lines.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the severity of facial lines using a photographic scale and self-assessment.

    Participants must not be pregnant or breastfeeding and must use effective contraception if applicable.

  3. Step 3

    Treatment administration

    Participants receive a single treatment of either IPN10200 or a placebo. The treatment is administered as an injection into the muscles of the face.

    The dosage is determined based on the study's dose escalation and dose-finding protocol.

  4. Step 4

    Follow-up assessments

    Follow-up assessments are conducted to monitor the safety and effectiveness of the treatment. These include physical and facial examinations, vital signs checks, and ECGs.

    Participants' responses to the treatment are evaluated through both investigator assessments and self-assessments at maximum contraction of facial muscles.

  5. Step 5

    Post-treatment visits

    Post-treatment visits occur at specified intervals to assess the duration and onset of the treatment response.

    Participants' satisfaction with their facial appearance is measured using a satisfaction scale.

  6. Step 6

    Final evaluation

    A final evaluation is conducted to determine the overall safety and efficacy of the treatment.

    The presence of antibodies against the treatment is checked at specific post-treatment visits.

Who can join the trial?

9 criteria

  • Participants must be between 18 and 65 years old at the time of signing the consent form.
  • Participants must be able to give signed consent, which means they understand and agree to the study's requirements and restrictions.
  • Participants must have the time and ability to complete the study and follow the study instructions.
  • Participants must not live in an institution due to a court or administrative order.
  • Participants must not be employees of the sponsor or the clinical research unit involved in the study, nor should they be immediate family members of such employees. Immediate family includes a spouse, parent, child, or sibling, whether biological or adopted.
  • Participants must have moderate to severe lines on their face, specifically in the upper facial area, as assessed by a doctor using a special scale.
  • Participants must be dissatisfied or very dissatisfied with their facial lines at the start of the study.
  • Both men and women can participate, but only women will be involved in dose escalation. Men must agree to use effective contraception if their partner could become pregnant, during the study and for 12 weeks after the study treatment.
  • Women must not be pregnant or breastfeeding. They must either be unable to have children or use an acceptable method of contraception during the study. Women who can have children must have a negative pregnancy test before starting the study.

Who cannot join the trial?

9 criteria

  • Participants with any known allergies to the study medication or its ingredients cannot join.
  • Individuals who have had any other facial cosmetic procedures recently may not be eligible.
  • People with certain skin conditions that affect the face might be excluded.
  • Participants who are pregnant or breastfeeding cannot take part in the study.
  • Anyone with a history of certain medical conditions that could interfere with the study results may not be allowed to participate.
  • Individuals currently taking medications that could affect the study outcomes might be excluded.
  • Participants who have been part of another clinical trial recently may not be eligible.
  • People with a history of drug or alcohol abuse might be excluded from the study.
  • Individuals who cannot comply with the study requirements or follow-up visits may not be able to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

IPN10200 is a treatment being studied for its ability to improve the appearance of moderate to severe upper facial lines in adults. The trial is designed to evaluate how safe and effective this treatment is when used in different doses. Participants in the study receive a single treatment of IPN10200, and the effects are measured by both the investigator's assessment and the participant's own assessment of their facial lines. The goal is to see if IPN10200 can reduce the appearance of these lines when the face is at maximum contraction.

What is already known about the treatment

IPN10200 – This medication is administered through injection and is currently being studied in clinical trials for its effectiveness in treating moderate to severe upper facial lines. It is in the investigational stage, with ongoing research to determine its safety and efficacy. The main therapeutic indication is the improvement of facial lines, specifically targeting areas such as glabellar lines, forehead lines, and lateral canthal lines. At the molecular level, IPN10200 works by modulating muscle activity to reduce the appearance of wrinkles. It is classified pharmacologically as a neuromodulator, similar to other treatments used for cosmetic purposes.

Investigated diseases

Upper Facial Lines – Upper facial lines refer to the wrinkles and creases that appear on the forehead, around the eyes, and between the eyebrows. These lines are often caused by repeated facial expressions such as frowning, squinting, or raising the eyebrows. Over time, the skin loses elasticity and collagen, making these lines more pronounced. They can vary in severity from mild to severe, depending on factors like age, genetics, and sun exposure. The progression of these lines can lead to a more aged appearance, often prompting individuals to seek cosmetic treatments.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-512782-14-00Protocol codeD-FR-10200-002Estimated enrolment771 patientsSponsorIpsen Innovation

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).